Trial to Test Potential HCV Triple Combination Therapy
Share
Follow Us
The Editors at Hepatitis Central
December 24, 2007
GI-5005 Tarmogen is under consideration as the third drug in a cocktail for treating chronic Hepatitis C. In an international Phase II trial just getting underway, GI-5005 will be paired with the current standard of therapy – pegylated interferon and ribavirin.
GlobeImmune Begins Trial With Hepatitis C Candidate
Dec. 20, 2007 | Vol. 5 No. 248
http://fdanews.com
GlobeImmune has started a Phase II trial to evaluate GI-5005 Tarmogen for the treatment of patients with chronic hepatitis C infection.
The drug is being evaluated as a potential therapy in combination with the standard of care, pegylated interferon plus ribavirin.
The randomized, open-label, multi-arm, multicenter trial is evaluating GI-5005 in combination with full duration standard of care versus standard of care alone in patients who are either treatment-naive or unresponsive to previous therapy.
This study will enroll 120 patients in the U.S., India and Europe, GlobeImmune said.
